<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00845156</url>
  </required_header>
  <id_info>
    <org_study_id>H6820-30422</org_study_id>
    <nct_id>NCT00845156</nct_id>
  </id_info>
  <brief_title>Alpha Lipoic Acid and Insulin Resistance</brief_title>
  <official_title>Alpha Lipoic Acid and Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects will be screened with a 2 hour oral glucose tolerance test. After this screening
      visit, their insulin resistance will be measured. Subjects will then be given either alpha
      lipoic acid (antioxidant) or placebo for 6 weeks. The insulin resistance test will be
      repeated after the 6 weeks. We believe these studies will confirm the beneficial effect of
      alpha lipoic acid on insulin sensitivity.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We propose to perform a placebo-controlled study of Alpha Lipoic Acid (LA) administration in
      a cohort of non-obese, non-diabetic, insulin resistant subjects. The insulin sensitivity of
      180 subjects will be initially estimated by measuring fasting glucose and insulin levels
      (homeostasis model assessment) and oral glucose tolerance test (OGTT). The 60 most insulin
      resistant subjects will then be randomized to 6 weeks of therapy with either 600 mg three
      times a day of LA or placebo. To quantitate the ALA-induced improvements, euglycemic
      hyperinsulinemic clamps to evaluate insulin sensitivity, OGTT using deuterated glucose to
      evaluate glycolytic glucose disposal, and muscle biopsies to evaluate insulin signaling
      pathways, will be performed before and after treatment. We believe these studies will (1)
      confirm the beneficial effect of CR-ALA on insulin sensitivity; (2) further our understanding
      of the molecular mechanisms of LA action; and (3) because these insulin resistant subjects
      are at risk for the development of type 2 diabetes, the Metabolic Syndrome, and coronary
      artery disease (CAD), a demonstration of the beneficial effects of LA on insulin action could
      ultimately have important public health consequences.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Resistance</measure>
    <time_frame>0 months and 4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Anti-Oxidant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alpha Lipoic Acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Alpha Lipoic Acid</intervention_name>
    <description>Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily</description>
    <arm_group_label>Anti-Oxidant</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, not exercising regularly

        Exclusion Criteria:

          -  Diabetes, Impaired glucose tolerance, Heart disease, Liver disease, HIV, abnormal TSH
             results, other abnormal lab values
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Umesh Masharani, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Martha Kennedy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 17, 2009</study_first_submitted>
  <study_first_submitted_qc>February 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2009</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes</keyword>
  <keyword>Insulin resistance</keyword>
  <keyword>healthy controls</keyword>
  <keyword>anti oxidants</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Thioctic Acid</mesh_term>
    <mesh_term>Antioxidants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

